Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Ophthalmic Drug

PUBLISHER: Grand View Research | PRODUCT CODE: 1908583

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1908583

Ophthalmic Drugs Market Size, Share & Trends Analysis Report By Drug Class (Steroidal drugs, Anti-VEGF Agents), By Disease, By Dosage Form, By Route of Administration, By Product, By Drug Type, By Region, And Segment Forecasts, 2026 - 2033

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 5950
Printable PDF & Excel (5-User License)
USD 6950
Printable PDF & Excel (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Ophthalmic Drugs Market Summary

The global ophthalmic drugs market size was valued at USD 41.39 billion in 2025 and is projected to reach USD 79.44 billion by 2033, growing at a CAGR of 8.51% from 2026 to 2033. The market growth is attributed to the rising prevalence of eye disease, advancements in drug delivery, and an increasing focus on research for development of novel therapeutics in the market.

Eye diseases encompass a wide spectrum of morbidities that impact various components of the visual system and function. The increase in the prevalence of eye-related disorders, such as macular degeneration, diabetic retinopathy, and presbyopia, is one of the major factors driving the growth of the overall ophthalmic drug market. The increasing prevalence of these conditions is expected to boost the market. As per WHO, in 2023, approximately 2.2 billion people were visually impaired globally. Moreover, according to a study, "Global incidence and risk factors for glaucoma," published by the Journal of Global Health in November 2024, the worldwide incidence rate of Primary Open-Angle Glaucoma (POAG) in 2022 was 23.46 cases per 10,000 person-years for individuals aged 40 to 79. Between 1990 and 2019, there was a notable rise in this rate, increasing from 5.51 cases per 10,000 person-years in the 40 to 44 age group to 64.36 cases per 10,000 person-years in the 75 to 79 age group. This rising prevalence of eye conditions significantly increases the demand for effective ophthalmic drugs over the forecast period.

The growing geriatric population is anticipated to increase the number of people with eye conditions. According to the United Nations, the share of individuals aged 65 and older is growing more rapidly than that of younger populations. As a result, the percentage of the global population in this age group is anticipated to increase from 10% in 2022 to 16% by 2050. By that year, it is estimated that the number of people aged 65 and above will be twice that of children under the age of 5 and nearly equal to the number of children under 12. Presbyopia, cataracts, glaucoma, and AMD become more common as people get older. This growing adult population, coupled with the increasing prevalence of conditions such as diabetes, significantly increases the risk of various eye conditions, thereby contributing to market growth. According to the WHO, the population of individuals diagnosed with diabetes increased from 200 million in 1990 to 830 million by 2022. Some eye disorders, such as glaucoma, refractive error, and retinal degeneration, including retinitis pigmentosa, are also influenced by genetics. Another non-modifiable risk factor associated with an increased risk of acquiring some eye disorders is ethnicity.

Global Ophthalmic Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global ophthalmic drugs market report on the basis of drug class, disease, dosage form, route of administration, product, drug type, and region:

  • Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
  • Anti-allergy
  • Anti-inflammatory
    • Non-steroidal drugs
    • Steroids
  • Anti-VEGF Agents
  • Anti-glaucoma
  • Others
  • Disease Outlook (Revenue, USD Million, 2021 - 2033)
  • Dry eye
    • Gels
    • Eye solutions & suspensions
    • Capsules & Tablets,
    • Eye drops
    • Ointments
  • Allergies
    • Gels
    • Eye solutions & suspensions
    • Capsules & Tablets,
    • Eye drops
    • Ointments
  • Glaucoma
    • Gels
    • Eye solutions & suspensions
    • Capsules & Tablets,
    • Eye drops
    • Ointments
  • Infection
    • Gels
    • Eye solutions & suspensions
    • Capsules & Tablets,
    • Eye drops
    • Ointments
  • Retinal Disorders
    • By Type
    • Macular Degeneration
    • Diabetic Retinopathy
    • Others
    • By Dosage Type
    • Gels
    • Eye solutions & suspensions
    • Capsules & Tablets,
    • Eye drops
    • Ointments
  • Uveitis
    • Gels
    • Eye solutions & suspensions
    • Capsules & Tablets,
    • Eye drops
    • Ointments
  • Others
    • Gels
    • Eye solutions & suspensions
    • Capsules & Tablets,
    • Eye drops
    • Ointments
  • Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Topical
  • Local Ocular
    • Subconjunctival
    • Intravitreal
    • Retrobulbar
    • Intracameral
  • Systemic
  • Dosage Form Outlook (Revenue, USD Million, 2021 - 2033)
  • Gels
  • Eye Solutions & Suspensions
  • Capsules and Tablets
  • Eye Drops
  • Ointments
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Prescription Drugs
  • OTC
  • Drug Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Branded Drugs
  • Generic Drugs
  • Regional Outlook (Revenue in USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Kuwait
Show more
Product Code: GVR-2-68038-010-1

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug class
    • 1.2.2. Disease
    • 1.2.3. Route of administration
    • 1.2.4. Dosage Form
    • 1.2.5. Product
    • 1.2.6. Drug type
    • 1.2.7. Regional scope
    • 1.2.8. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug class outlook
    • 2.2.2. Disease outlook
    • 2.2.3. Route of administration outlook
    • 2.2.4. Dosage Form outlook
    • 2.2.5. Product outlook
    • 2.2.6. Drug type outlook
    • 2.2.7. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Ophthalmic Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing diseases prevalence
      • 3.2.1.2. String development pipeline
      • 3.2.1.3. Advancements in drug delivery
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Patent expiry of blockbuster drugs
  • 3.3. Ophthalmic Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Ophthalmic Drugs Market: Drug Class Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Ophthalmic Drugs Market: Drug Class Movement Analysis
  • 4.3. Ophthalmic Drugs Market Size & Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
  • 4.4. Anti-Allergy
    • 4.4.1. Anti-Allergy market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5. Anti-VEGF agents
    • 4.5.1. Anti-VEGF agents market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.6. Anti-inflammatory
    • 4.6.1. Anti-inflammatory market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.6.2. Non-steroidal Drugs
      • 4.6.2.1. Non-steroidal Drugs market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.6.3. Steroids
      • 4.6.3.1. Steroids market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.7. Anti-glaucoma
    • 4.7.1. Anti-glaucoma market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.8. Gene & Cell Therapy
    • 4.8.1. Gene & Cell Therapy market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.9. Others
    • 4.9.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. Ophthalmic Drugs Market: Disease Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Ophthalmic Drugs Market: Disease Movement Analysis
  • 5.3. Ophthalmic Drugs Market Size & Trend Analysis, by Disease, 2021 to 2033 (USD Million)
  • 5.4. Dry eye
    • 5.4.1. Dry eye market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.4.1.1. Gels
        • 5.4.1.1.1. Gels market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.4.1.2. Eye solutions & suspensions
        • 5.4.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.4.1.3. Capsules & tablets
        • 5.4.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.4.1.4. Eye drops
        • 5.4.1.4.1. Eye drops market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.4.1.5. Ointments
        • 5.4.1.5.1. Ointments market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.5. Allergies
    • 5.5.1. Allergies market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.5.1.1. Gels
        • 5.5.1.1.1. Gels market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.5.1.2. Eye solutions & suspensions
        • 5.5.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.5.1.3. Capsules & tablets
        • 5.5.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.5.1.4. Eye drops
        • 5.5.1.4.1. Eye drops market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.5.1.5. Ointments
        • 5.5.1.5.1. Ointments market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.6. Glaucoma
    • 5.6.1. Glaucoma market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.6.1.1. Gels
        • 5.6.1.1.1. Gels market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.6.1.2. Eye solutions & suspensions
        • 5.6.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.6.1.3. Capsules & tablets
        • 5.6.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.6.1.4. Eye drops
        • 5.6.1.4.1. Eye drops market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.6.1.5. Ointments
        • 5.6.1.5.1. Ointments market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.7. Infection
    • 5.7.1. Infection market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.7.1.1. Gels
        • 5.7.1.1.1. Gels market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.7.1.2. Eye solutions & suspensions
        • 5.7.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.7.1.3. Capsules & tablets
        • 5.7.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.7.1.4. Eye drops
        • 5.7.1.4.1. Eye drops market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.7.1.5. Ointments
        • 5.7.1.5.1. Ointments market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.8. Retinal Disorders
    • 5.8.1. Retinal disorders market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.8.2. By Dosage Type
      • 5.8.2.1. Gels
        • 5.8.2.1.1. Gels market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.8.2.2. Eye solutions & suspensions
        • 5.8.2.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.8.2.3. Capsules & tablets
        • 5.8.2.3.1. Capsules & tablets market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.8.2.4. Eye drops
        • 5.8.2.4.1. Eye drops market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.8.2.5. Ointments
        • 5.8.2.5.1. Ointments market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 5.8.3. By Type
      • 5.8.3.1. Macular degeneration
        • 5.8.3.1.1. Macular degeneration market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.8.3.2. Diabetic retinopathy
        • 5.8.3.2.1. Diabetic retinopathy market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.8.3.3. Others
        • 5.8.3.3.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.9. Uveitis
    • 5.9.1. Uveitis market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.9.1.1. Gels
        • 5.9.1.1.1. Gels market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.9.1.2. Eye solutions & suspensions
        • 5.9.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.9.1.3. Capsules & tablets
        • 5.9.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.9.1.4. Eye drops
        • 5.9.1.4.1. Eye drops market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.9.1.5. Ointments
        • 5.9.1.5.1. Ointments market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 5.10. Others
    • 5.10.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.10.1.1. Gels
        • 5.10.1.1.1. Gels market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.10.1.2. Eye solutions & suspensions
        • 5.10.1.2.1. Eye solutions & suspensions market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.10.1.3. Capsules & tablets
        • 5.10.1.3.1. Capsules & tablets market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.10.1.4. Eye drops
        • 5.10.1.4.1. Eye drops market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 5.10.1.5. Ointments
        • 5.10.1.5.1. Ointments market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Ophthalmic Drugs Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Ophthalmic Drugs Market: Route of Administration Movement Analysis
  • 6.3. Ophthalmic Drugs Market Size & Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
  • 6.4. Topical
    • 6.4.1. Topical market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5. Local Ocular
    • 6.5.1. Local ocular market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 6.5.1.1. Subconjunctival
        • 6.5.1.1.1. Subconjunctival market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 6.5.1.2. Intravitreal
        • 6.5.1.2.1. Intravitreal market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 6.5.1.3. Retrobulbar
        • 6.5.1.3.1. Retrobulbar market revenue estimates and forecasts, 2021 - 2033 (USD Million)
      • 6.5.1.4. Intracameral
        • 6.5.1.4.1. Intracameral market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.6. Sytemic
    • 6.6.1. Sytemic market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Ophthalmic Drugs Market: Dosage Form Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Ophthalmic Drugs Market: Dosage Form Movement Analysis
  • 7.3. Ophthalmic Drugs Market Size & Trend Analysis, by Dosage Form, 2021 to 2033 (USD Million)
  • 7.4. Gels
    • 7.4.1. Gels market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5. Eye solutions & suspensions
    • 7.5.1. Eye solutions & suspensions market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6. Capsules & Tablets
    • 7.6.1. Capsules & tablets market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7. Eye drops
    • 7.7.1. Eye drops market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.8. Ointments
    • 7.8.1. Ointments market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Ophthalmic Drugs Market: Product Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Ophthalmic Drugs Market: Product Movement Analysis
  • 8.3. Ophthalmic Drugs Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
  • 8.4. OTC
    • 8.4.1. OTC market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.5. Prescription Drugs
    • 8.5.1. Prescription drugs market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 9. Ophthalmic Drugs Market: Drug Type Estimates & Trend Analysis

  • 9.1. Segment Dashboard
  • 9.2. Ophthalmic Drugs Market: Drug Type Movement Analysis
  • 9.3. Ophthalmic Drugs Market Size & Trend Analysis, by Drug Type, 2021 to 2033 (USD Million)
  • 9.4. Branded Drugs
    • 9.4.1. Branded drugs market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 9.5. Generic Drugs
    • 9.5.1. Generic drugs market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 10. Ophthalmic Drugs Market: Regional Estimates & Trend Analysis

  • 10.1. Regional Market Share Analysis, 2025 & 2033
  • 10.2. Regional Market Dashboard
  • 10.3. Global Regional Market Snapshot
  • 10.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
  • 10.5. North America
    • 10.5.1. U.S.
      • 10.5.1.1. Key country dynamics
      • 10.5.1.2. Regulatory framework/Reimbursement
      • 10.5.1.3. Competitive scenario
      • 10.5.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.5.2. Canada
      • 10.5.2.1. Key country dynamics
      • 10.5.2.2. Regulatory framework/Reimbursement
      • 10.5.2.3. Competitive scenario
      • 10.5.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.5.3. Mexico
      • 10.5.3.1. Key country dynamics
      • 10.5.3.2. Regulatory framework/Reimbursement
      • 10.5.3.3. Competitive scenario
      • 10.5.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.6. Europe
    • 10.6.1. UK
      • 10.6.1.1. Key country dynamics
      • 10.6.1.2. Regulatory framework/Reimbursement
      • 10.6.1.3. Competitive scenario
      • 10.6.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.6.2. Germany
      • 10.6.2.1. Key country dynamics
      • 10.6.2.2. Regulatory framework/Reimbursement
      • 10.6.2.3. Competitive scenario
      • 10.6.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.6.3. France
      • 10.6.3.1. Key country dynamics
      • 10.6.3.2. Regulatory framework/Reimbursement
      • 10.6.3.3. Competitive scenario
      • 10.6.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.6.4. Italy
      • 10.6.4.1. Key country dynamics
      • 10.6.4.2. Regulatory framework/Reimbursement
      • 10.6.4.3. Competitive scenario
      • 10.6.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.6.5. Spain
      • 10.6.5.1. Key country dynamics
      • 10.6.5.2. Regulatory framework/Reimbursement
      • 10.6.5.3. Competitive scenario
      • 10.6.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.6.6. Norway
      • 10.6.6.1. Key country dynamics
      • 10.6.6.2. Regulatory framework/Reimbursement
      • 10.6.6.3. Competitive scenario
      • 10.6.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.6.7. Sweden
      • 10.6.7.1. Key country dynamics
      • 10.6.7.2. Regulatory framework/Reimbursement
      • 10.6.7.3. Competitive scenario
      • 10.6.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.6.8. Denmark
      • 10.6.8.1. Key country dynamics
      • 10.6.8.2. Regulatory framework/Reimbursement
      • 10.6.8.3. Competitive scenario
      • 10.6.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.7. Asia Pacific
    • 10.7.1. Japan
      • 10.7.1.1. Key country dynamics
      • 10.7.1.2. Regulatory framework/Reimbursement
      • 10.7.1.3. Competitive scenario
      • 10.7.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.7.2. China
      • 10.7.2.1. Key country dynamics
      • 10.7.2.2. Regulatory framework/Reimbursement
      • 10.7.2.3. Competitive scenario
      • 10.7.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.7.3. India
      • 10.7.3.1. Key country dynamics
      • 10.7.3.2. Regulatory framework/Reimbursement
      • 10.7.3.3. Competitive scenario
      • 10.7.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.7.4. Australia
      • 10.7.4.1. Key country dynamics
      • 10.7.4.2. Regulatory framework/Reimbursement
      • 10.7.4.3. Competitive scenario
      • 10.7.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.7.5. South Korea
      • 10.7.5.1. Key country dynamics
      • 10.7.5.2. Regulatory framework/Reimbursement
      • 10.7.5.3. Competitive scenario
      • 10.7.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.7.6. Thailand
      • 10.7.6.1. Key country dynamics
      • 10.7.6.2. Regulatory framework/Reimbursement
      • 10.7.6.3. Competitive scenario
      • 10.7.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.8. Latin America
    • 10.8.1. Brazil
      • 10.8.1.1. Key country dynamics
      • 10.8.1.2. Regulatory framework/Reimbursement
      • 10.8.1.3. Competitive scenario
      • 10.8.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.8.2. Argentina
      • 10.8.2.1. Key country dynamics
      • 10.8.2.2. Regulatory framework/Reimbursement
      • 10.8.2.3. Competitive scenario
      • 10.8.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 10.9. Middle East and Africa
    • 10.9.1. South Africa
      • 10.9.1.1. Key country dynamics
      • 10.9.1.2. Regulatory framework/Reimbursement
      • 10.9.1.3. Competitive scenario
      • 10.9.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.9.2. Saudi Arabia
      • 10.9.2.1. Key country dynamics
      • 10.9.2.2. Regulatory framework/Reimbursement
      • 10.9.2.3. Competitive scenario
      • 10.9.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.9.3. UAE
      • 10.9.3.1. Key country dynamics
      • 10.9.3.2. Regulatory framework/Reimbursement
      • 10.9.3.3. Competitive scenario
      • 10.9.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
    • 10.9.4. Kuwait
      • 10.9.4.1. Key country dynamics
      • 10.9.4.2. Regulatory framework
      • 10.9.4.3. Competitive scenario
      • 10.9.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 11. Competitive Landscape

  • 11.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 11.2. Company/Competition Categorization
  • 11.3. Vendor Landscape
    • 11.3.1. List of key distributors and channel partners
    • 11.3.2. Key customers
    • 11.3.3. Key company market share analysis, 2023
    • 11.3.4. Alcon
      • 11.3.4.1. Company overview
      • 11.3.4.2. Financial performance
      • 11.3.4.3. Services benchmarking
      • 11.3.4.4. Strategic initiatives
    • 11.3.5. Novartis AG
      • 11.3.5.1. Company overview
      • 11.3.5.2. Financial performance
      • 11.3.5.3. Services benchmarking
      • 11.3.5.4. Strategic initiatives
    • 11.3.6. Bausch Health Companies, Inc.
      • 11.3.6.1. Company overview
      • 11.3.6.2. Financial performance
      • 11.3.6.3. Services benchmarking
      • 11.3.6.4. Strategic initiatives
    • 11.3.7. Merck & Co., Inc.
      • 11.3.7.1. Company overview
      • 11.3.7.2. Financial performance
      • 11.3.7.3. Services benchmarking
      • 11.3.7.4. Strategic initiatives
    • 11.3.8. Regeneron Pharmaceuticals, Inc.
      • 11.3.8.1. Company overview
      • 11.3.8.2. Financial performance
      • 11.3.8.3. Services benchmarking
      • 11.3.8.4. Strategic initiatives
    • 11.3.9. Coherus BioSciences, Inc.
      • 11.3.9.1. Company overview
      • 11.3.9.2. Financial performance
      • 11.3.9.3. Services benchmarking
      • 11.3.9.4. Strategic initiatives
    • 11.3.10. AbbVie, Inc. (Allergan)
      • 11.3.10.1. Company overview
      • 11.3.10.2. Financial performance
      • 11.3.10.3. Services benchmarking
      • 11.3.10.4. Strategic initiatives
    • 11.3.11. Pfizer, Inc.
      • 11.3.11.1. Company overview
      • 11.3.11.2. Financial performance
      • 11.3.11.3. Services benchmarking
      • 11.3.11.4. Strategic initiatives
    • 11.3.12. Bayer AG
      • 11.3.12.1. Company overview
      • 11.3.12.2. Financial performance
      • 11.3.12.3. Services benchmarking
      • 11.3.12.4. Strategic initiatives
    • 11.3.13. Santen Pharmaceutical Co., Ltd.
      • 11.3.13.1. Company overview
      • 11.3.13.2. Financial performance
      • 11.3.13.3. Services benchmarking
      • 11.3.13.4. Strategic initiatives
    • 11.3.14. Roche (Genentech, Inc.)
      • 11.3.14.1. Company overview
      • 11.3.14.2. Financial performance
      • 11.3.14.3. Services benchmarking
      • 11.3.14.4. Strategic initiatives
    • 11.3.15. Nicox
      • 11.3.15.1. Company overview
      • 11.3.15.2. Financial performance
      • 11.3.15.3. Services benchmarking
      • 11.3.15.4. Strategic initiatives
Show more
Product Code: GVR-2-68038-010-1

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America ophthalmic drugs market, by region, 2021 - 2033 (USD Million)
  • Table 3 North America ophthalmic drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 4 North America ophthalmic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 5 North America ophthalmic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 6 North America ophthalmic drugs market, by dosage form, 2021 - 2033 (USD Million)
  • Table 7 North America ophthalmic drugs market, by Product, 2021 - 2033 (USD Million)
  • Table 8 North America ophthalmic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 9 U.S. ophthalmic drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 10 U.S. ophthalmic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 11 U.S. ophthalmic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 12 U.S. ophthalmic drugs market, by dosage form, 2021 - 2033 (USD Million)
  • Table 13 U.S. ophthalmic drugs market, by Product, 2021 - 2033 (USD Million)
  • Table 14 U.S. ophthalmic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 15 Canada ophthalmic drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 16 Canada ophthalmic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 17 Canada ophthalmic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 18 Canada ophthalmic drugs market, by dosage form, 2021 - 2033 (USD Million)
  • Table 19 Canada ophthalmic drugs market, by Product, 2021 - 2033 (USD Million)
  • Table 20 Canada ophthalmic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 21 Mexico ophthalmic drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 22 Mexico ophthalmic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 23 Mexico ophthalmic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 24 Mexico ophthalmic drugs market, by dosage form, 2021 - 2033 (USD Million)
  • Table 25 Mexico ophthalmic drugs market, by Product, 2021 - 2033 (USD Million)
  • Table 26 Mexico ophthalmic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 27 Europe ophthalmic drugs market, by region, 2021 - 2033 (USD Million)
  • Table 28 Europe ophthalmic drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 29 Europe ophthalmic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 30 Europe ophthalmic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 31 Europe ophthalmic drugs market, by dosage form, 2021 - 2033 (USD Million)
  • Table 32 Europe ophthalmic drugs market, by Product, 2021 - 2033 (USD Million)
  • Table 33 Europe ophthalmic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 34 UK ophthalmic drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 35 UK ophthalmic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 36 UK ophthalmic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 37 UK ophthalmic drugs market, by dosage form, 2021 - 2033 (USD Million)
  • Table 38 UK ophthalmic drugs market, by Product, 2021 - 2033 (USD Million)
  • Table 39 UK ophthalmic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 40 Germany ophthalmic drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 41 Germany ophthalmic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 42 Germany ophthalmic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 43 Germany ophthalmic drugs market, by dosage form, 2021 - 2033 (USD Million)
  • Table 44 Germany ophthalmic drugs market, by Product, 2021 - 2033 (USD Million)
  • Table 45 Germany ophthalmic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 46 France ophthalmic drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 47 France ophthalmic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 48 France ophthalmic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 49 France ophthalmic drugs market, by dosage form, 2021 - 2033 (USD Million)
  • Table 50 France ophthalmic drugs market, by Product, 2021 - 2033 (USD Million)
  • Table 51 France ophthalmic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 52 Italy ophthalmic drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 53 Italy ophthalmic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 54 Italy ophthalmic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 55 Italy ophthalmic drugs market, by dosage form, 2021 - 2033 (USD Million)
  • Table 56 Italy ophthalmic drugs market, by Product, 2021 - 2033 (USD Million)
  • Table 57 Italy ophthalmic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 58 Spain ophthalmic drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 59 Spain ophthalmic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 60 Spain ophthalmic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 61 Spain ophthalmic drugs market, by dosage form, 2021 - 2033 (USD Million)
  • Table 62 Spain ophthalmic drugs market, by Product, 2021 - 2033 (USD Million)
  • Table 63 Spain ophthalmic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 64 Denmark ophthalmic drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 65 Denmark ophthalmic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 66 Denmark ophthalmic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 67 Denmark ophthalmic drugs market, by dosage form, 2021 - 2033 (USD Million)
  • Table 68 Denmark ophthalmic drugs market, by Product, 2021 - 2033 (USD Million)
  • Table 69 Denmark ophthalmic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 70 Sweden ophthalmic drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 71 Sweden ophthalmic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 72 Sweden ophthalmic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 73 Sweden ophthalmic drugs market, by dosage form, 2021 - 2033 (USD Million)
  • Table 74 Sweden ophthalmic drugs market, by Product, 2021 - 2033 (USD Million)
  • Table 75 Sweden ophthalmic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 76 Norway ophthalmic drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 77 Norway ophthalmic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 78 Norway ophthalmic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 79 Norway ophthalmic drugs market, by dosage form, 2021 - 2033 (USD Million)
  • Table 80 Norway ophthalmic drugs market, by Product, 2021 - 2033 (USD Million)
  • Table 81 Norway ophthalmic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 82 Asia Pacific ophthalmic drugs market, by region, 2021 - 2033 (USD Million)
  • Table 83 Asia Pacific ophthalmic drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 84 Asia Pacific ophthalmic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 85 Asia Pacific ophthalmic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 86 Asia Pacific ophthalmic drugs market, by dosage form, 2021 - 2033 (USD Million)
  • Table 87 Asia Pacific ophthalmic drugs market, by Product, 2021 - 2033 (USD Million)
  • Table 88 China ophthalmic drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 89 China ophthalmic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 90 China ophthalmic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 91 China ophthalmic drugs market, by dosage form, 2021 - 2033 (USD Million)
  • Table 92 China ophthalmic drugs market, by Product, 2021 - 2033 (USD Million)
  • Table 93 China ophthalmic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 94 Japan ophthalmic drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 95 Japan ophthalmic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 96 Japan ophthalmic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 97 Japan ophthalmic drugs market, by dosage form, 2021 - 2033 (USD Million)
  • Table 98 Japan ophthalmic drugs market, by Product, 2021 - 2033 (USD Million)
  • Table 99 Japan ophthalmic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 100 India ophthalmic drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 101 India ophthalmic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 102 India ophthalmic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 103 India ophthalmic drugs market, by dosage form, 2021 - 2033 (USD Million)
  • Table 104 India ophthalmic drugs market, by Product, 2021 - 2033 (USD Million)
  • Table 105 India ophthalmic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 106 Australia ophthalmic drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 107 Australia ophthalmic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 108 Australia ophthalmic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 109 Australia ophthalmic drugs market, by dosage form, 2021 - 2033 (USD Million)
  • Table 110 Australia ophthalmic drugs market, by Product, 2021 - 2033 (USD Million)
  • Table 111 Australia ophthalmic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 112 South Korea ophthalmic drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 113 South Korea ophthalmic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 114 South Korea ophthalmic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 115 South Korea ophthalmic drugs market, by dosage form, 2021 - 2033 (USD Million)
  • Table 116 South Korea ophthalmic drugs market, by Product, 2021 - 2033 (USD Million)
  • Table 117 South Korea ophthalmic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 118 Thailand ophthalmic drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 119 Thailand ophthalmic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 120 Thailand ophthalmic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 121 Thailand ophthalmic drugs market, by dosage form, 2021 - 2033 (USD Million)
  • Table 122 Thailand ophthalmic drugs market, by Product, 2021 - 2033 (USD Million)
  • Table 123 Thailand ophthalmic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 124 Latin America ophthalmic drugs market, by region, 2021 - 2033 (USD Million)
  • Table 125 Latin America ophthalmic drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 126 Latin America ophthalmic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 127 Latin America ophthalmic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 128 Latin America ophthalmic drugs market, by dosage form, 2021 - 2033 (USD Million)
  • Table 129 Latin America ophthalmic drugs market, by Product, 2021 - 2033 (USD Million)
  • Table 130 Latin America ophthalmic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 131 Brazil ophthalmic drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 132 Brazil ophthalmic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 133 Brazil ophthalmic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 134 Brazil ophthalmic drugs market, by dosage form, 2021 - 2033 (USD Million)
  • Table 135 Brazil ophthalmic drugs market, by Product, 2021 - 2033 (USD Million)
  • Table 136 Brazil ophthalmic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 137 Argentina ophthalmic drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 138 Argentina ophthalmic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 139 Argentina ophthalmic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 140 Argentina ophthalmic drugs market, by dosage form, 2021 - 2033 (USD Million)
  • Table 141 Argentina ophthalmic drugs market, by Product, 2021 - 2033 (USD Million)
  • Table 142 Argentina ophthalmic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 143 Middle East and Africa ophthalmic drugs market, by region, 2021 - 2033 (USD Million)
  • Table 144 Middle East and Africa ophthalmic drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 145 Middle East and Africa ophthalmic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 146 Middle East and Africa ophthalmic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 147 Middle East and Africa ophthalmic drugs market, by dosage form, 2021 - 2033 (USD Million)
  • Table 148 Middle East and Africa ophthalmic drugs market, by Product, 2021 - 2033 (USD Million)
  • Table 149 Middle East and Africa ophthalmic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 150 South Africa ophthalmic drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 151 South Africa ophthalmic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 152 South Africa ophthalmic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 153 South Africa ophthalmic drugs market, by dosage form, 2021 - 2033 (USD Million)
  • Table 154 South Africa ophthalmic drugs market, by Product, 2021 - 2033 (USD Million)
  • Table 155 South Africa ophthalmic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 156 Saudi Arabia ophthalmic drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 157 Saudi Arabia ophthalmic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 158 Saudi Arabia ophthalmic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 159 Saudi Arabia ophthalmic drugs market, by dosage form, 2021 - 2033 (USD Million)
  • Table 160 Saudi Arabia ophthalmic drugs market, by Product, 2021 - 2033 (USD Million)
  • Table 161 Saudi Arabia ophthalmic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 162 UAE ophthalmic drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 163 UAE ophthalmic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 164 UAE ophthalmic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 165 UAE ophthalmic drugs market, by dosage form, 2021 - 2033 (USD Million)
  • Table 166 UAE ophthalmic drugs market, by Product, 2021 - 2033 (USD Million)
  • Table 167 UAE ophthalmic drugs market, by drug type, 2021 - 2033 (USD Million)
  • Table 168 Kuwait ophthalmic drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 169 Kuwait ophthalmic drugs market, by disease, 2021 - 2033 (USD Million)
  • Table 170 Kuwait ophthalmic drugs market, by route of administration, 2021 - 2033 (USD Million)
  • Table 171 Kuwait ophthalmic drugs market, by dosage form, 2021 - 2033 (USD Million)
  • Table 172 Kuwait ophthalmic drugs market, by Product, 2021 - 2033 (USD Million)
  • Table 173 Kuwait ophthalmic drugs market, by drug type, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in Middle East and Africa
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Ophthalmic drugs market: market outlook
  • Fig. 14 Ophthalmic drugs competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Ophthalmic drugs market driver impact
  • Fig. 20 Ophthalmic drugs market restraint impact
  • Fig. 21 Ophthalmic drugs market strategic initiatives analysis
  • Fig. 22 Ophthalmic drugs market: Drug class movement analysis
  • Fig. 23 Ophthalmic drugs market: Drug class outlook and key takeaways
  • Fig. 24 Anti-Allergy market estimates and forecasts, 2021 - 2033
  • Fig. 25 Anti-VEGF agents market estimates and forecasts, 2021 - 2033
  • Fig. 26 Anti-inflammatory market estimates and forecasts, 2021 - 2033
  • Fig. 27 Non steroidal drugs market estimates and forecasts, 2021 - 2033
  • Fig. 28 Steroidal drugs market estimates and forecasts, 2021 - 2033
  • Fig. 29 Anti glaucoma market estimates and forecasts, 2021 - 2033
  • Fig. 30 Gene & cell therapy market estimates and forecasts, 2021 - 2033
  • Fig. 31 Others market estimates and forecasts, 2021 - 2033
  • Fig. 32 Ophthalmic drugs market: Disease movement analysis
  • Fig. 33 Ophthalmic drugs market: Disease outlook and key takeaways
  • Fig. 34 Dry eye market estimates and forecasts, 2021 - 2033
  • Fig. 35 Gels market estimates and forecasts, 2021 - 2033
  • Fig. 36 Eye solutions & suspensions market estimates and forecasts, 2021 - 2033
  • Fig. 37 Capsules & tablets market estimates and forecasts, 2021 - 2033
  • Fig. 38 Eye drops market estimates and forecasts, 2021 - 2033
  • Fig. 39 Ointments market estimates and forecasts, 2021 - 2033
  • Fig. 40 Allergies market estimates and forecasts, 2021 - 2033
  • Fig. 41 Gels market estimates and forecasts, 2021 - 2033
  • Fig. 42 Eye solutions & suspensions market estimates and forecasts, 2021 - 2033
  • Fig. 43 Capsules & tablets market estimates and forecasts, 2021 - 2033
  • Fig. 44 Eye drops market estimates and forecasts, 2021 - 2033
  • Fig. 45 Ointments market estimates and forecasts, 2021 - 2033
  • Fig. 46 Glaucoma market estimates and forecasts, 2021 - 2033
  • Fig. 47 Gels market estimates and forecasts, 2021 - 2033
  • Fig. 48 Eye solutions & suspensions market estimates and forecasts, 2021 - 2033
  • Fig. 49 Capsules & tablets market estimates and forecasts, 2021 - 2033
  • Fig. 50 Eye drops market estimates and forecasts, 2021 - 2033
  • Fig. 51 Ointments market estimates and forecasts, 2021 - 2033
  • Fig. 52 Infection market estimates and forecasts, 2021 - 2033
  • Fig. 53 Gels market estimates and forecasts, 2021 - 2033
  • Fig. 54 Eye solutions & suspensions market estimates and forecasts, 2021 - 2033
  • Fig. 55 Capsules & tablets market estimates and forecasts, 2021 - 2033
  • Fig. 56 Eye drops market estimates and forecasts, 2021 - 2033
  • Fig. 57 Ointments market estimates and forecasts, 2021 - 2033
  • Fig. 58 Retinal disorders market estimates and forecasts, 2021 - 2033
  • Fig. 59 By type market estimates and forecasts, 2021 - 2033
  • Fig. 60 Macular degeneration market estimates and forecasts, 2021 - 2033
  • Fig. 61 Diabetic retinopathy market estimates and forecasts, 2021 - 2033
  • Fig. 62 Others market estimates and forecasts, 2021 - 2033
  • Fig. 63 By dosage type market estimates and forecasts, 2021 - 2033
  • Fig. 64 Gels market estimates and forecasts, 2021 - 2033
  • Fig. 65 Eye solutions & suspensions market estimates and forecasts, 2021 - 2033
  • Fig. 66 Capsules & tablets market estimates and forecasts, 2021 - 2033
  • Fig. 67 Eye drops market estimates and forecasts, 2021 - 2033
  • Fig. 68 Ointments market estimates and forecasts, 2021 - 2033
  • Fig. 69 Uveitis market estimates and forecasts, 2021 - 2033
  • Fig. 70 Gels market estimates and forecasts, 2021 - 2033
  • Fig. 71 Eye solutions & suspensions market estimates and forecasts, 2021 - 2033
  • Fig. 72 Capsules & tablets market estimates and forecasts, 2021 - 2033
  • Fig. 73 Eye drops market estimates and forecasts, 2021 - 2033
  • Fig. 74 Ointments market estimates and forecasts, 2021 - 2033
  • Fig. 75 Others market estimates and forecasts, 2021 - 2033
  • Fig. 76 Gels market estimates and forecasts, 2021 - 2033
  • Fig. 77 Eye solutions & suspensions market estimates and forecasts, 2021 - 2033
  • Fig. 78 Capsules & tablets market estimates and forecasts, 2021 - 2033
  • Fig. 79 Eye drops market estimates and forecasts, 2021 - 2033
  • Fig. 80 Ointments market estimates and forecasts, 2021 - 2033
  • Fig. 81 Ophthalmic drugs market: Dosage form movement analysis
  • Fig. 82 Ophthalmic drugs market: Dosage form outlook and key takeaways
  • Fig. 83 Gels market estimates and forecasts, 2021 - 2033
  • Fig. 84 Eye solutions & suspensions market estimates and forecasts, 2021 - 2033
  • Fig. 85 Capsules & tablets market estimates and forecasts, 2021 - 2033
  • Fig. 86 Eye drops market estimates and forecasts, 2021 - 2033
  • Fig. 87 Ointments market estimates and forecasts, 2021 - 2033
  • Fig. 88 Ophthalmic drugs market: Route of administration movement analysis
  • Fig. 89 Ophthalmic drugs market: Route of administration outlook and key takeaways
  • Fig. 90 Topical market estimates and forecasts, 2021 - 2033
  • Fig. 91 Local Ocular market estimates and forecasts, 2021 - 2033
  • Fig. 92 Subconjunctival market estimates and forecasts, 2021 - 2033
  • Fig. 93 Intravitreal market estimates and forecasts, 2021 - 2033
  • Fig. 94 Retrobulbar market estimates and forecasts, 2021 - 2033
  • Fig. 95 Intracameral market estimates and forecasts, 2021 - 2033
  • Fig. 96 Sytemic market estimates and forecasts, 2021 - 2033
  • Fig. 97 Ophthalmic drugs market: Product movement analysis
  • Fig. 98 Ophthalmic drugs market: Product outlook and key takeaways
  • Fig. 99 OTC market estimates and forecasts, 2021 - 2033
  • Fig. 100 Prescription drugs market estimates and forecasts, 2021 - 2033
  • Fig. 101 Ophthalmic drugs market: Drug type movement analysis
  • Fig. 102 Ophthalmic drugs market: Drug type outlook and key takeaways
  • Fig. 103 Branded drugs market estimates and forecasts, 2021 - 2033
  • Fig. 104 Generic drugs market estimates and forecasts, 2021 - 2033
  • Fig. 105 Global ophthalmic drugs market: Regional movement analysis
  • Fig. 106 Global ophthalmic drugs market: Regional outlook and key takeaways
  • Fig. 107 Global ophthalmic drugs market share and leading players
  • Fig. 108 North America market share and leading players
  • Fig. 109 Europe market share and leading players
  • Fig. 110 Asia Pacific market share and leading players
  • Fig. 111 Latin America market share and leading players
  • Fig. 112 Middle East & Africa market share and leading players
  • Fig. 113 North America, by country
  • Fig. 114 North America
  • Fig. 115 North America market estimates and forecasts, 2021 - 2033
  • Fig. 116 U.S. key country dynamics
  • Fig. 117 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 118 Canada country dynamics
  • Fig. 119 Canada market estimates and forecasts, 2021 - 2033
  • Fig. 120 Mexico country dynamics
  • Fig. 121 Mexico market estimates and forecasts, 2021 - 2033
  • Fig. 122 Europe
  • Fig. 123 Europe market estimates and forecasts, 2021 - 2033
  • Fig. 124 UK country dynamics
  • Fig. 125 UK market estimates and forecasts, 2021 - 2033
  • Fig. 126 Germany
  • Fig. 127 Germany market estimates and forecasts, 2021 - 2033
  • Fig. 128 France country dynamics
  • Fig. 129 France market estimates and forecasts, 2021 - 2033
  • Fig. 130 Italy country dynamics
  • Fig. 131 Italy market estimates and forecasts, 2021 - 2033
  • Fig. 132 Spain country dynamics
  • Fig. 133 Spain market estimates and forecasts, 2021 - 2033
  • Fig. 134 Denmark country dynamics
  • Fig. 135 Denmark market estimates and forecasts, 2021 - 2033
  • Fig. 136 Sweden country dynamics
  • Fig. 137 Sweden market estimates and forecasts, 2021 - 2033
  • Fig. 138 Norway country dynamics
  • Fig. 139 Norway market estimates and forecasts, 2021 - 2033
  • Fig. 140 Asia Pacific
  • Fig. 141 Asia Pacific market estimates and forecasts, 2021 - 2033
  • Fig. 142 China country dynamics
  • Fig. 143 China market estimates and forecasts, 2021 - 2033
  • Fig. 144 Japan country dynamics
  • Fig. 145 Japan market estimates and forecasts, 2021 - 2033
  • Fig. 146 India country dynamics
  • Fig. 147 India market estimates and forecasts, 2021 - 2033
  • Fig. 148 Thailand country dynamics
  • Fig. 149 Thailand market estimates and forecasts, 2021 - 2033
  • Fig. 150 South Korea country dynamics
  • Fig. 151 South Korea market estimates and forecasts, 2021 - 2033
  • Fig. 152 Australia country dynamics
  • Fig. 153 Australia market estimates and forecasts, 2021 - 2033
  • Fig. 154 Latin America
  • Fig. 155 Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 156 Brazil country dynamics
  • Fig. 157 Brazil market estimates and forecasts, 2021 - 2033
  • Fig. 158 Argentina country dynamics
  • Fig. 159 Argentina market estimates and forecasts, 2021 - 2033
  • Fig. 160 Middle East and Africa
  • Fig. 161 Middle East and Africa market estimates and forecasts, 2021 - 2033
  • Fig. 162 South Africa country dynamics
  • Fig. 163 South Africa market estimates and forecasts, 2021 - 2033
  • Fig. 164 Saudi Arabia country dynamics
  • Fig. 165 Saudi Arabia market estimates and forecasts, 2021 - 2033
  • Fig. 166 UAE country dynamics
  • Fig. 167 UAE market estimates and forecasts, 2021 - 2033
  • Fig. 168 Kuwait country dynamics
  • Fig. 169 Kuwait market estimates and forecasts, 2021 - 2033
  • Fig. 170 Market share of key market players- Syndromic multiplex diagnostics market, 2025
  • Fig. 171 Company Categorization
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!